Yumanity Therapeutics (YMTX)
NASDAQ:YMTX

Yumanity Therapeutics (YMTX) Stock Forecast & Price Target

642 Followers
See the Price Targets and Ratings of:

YMTX Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Yumanity
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

YMTX Stock 12 Months Forecast

There Are No Analyst Ratings for YMTX In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Piper Sandler
$9.00
Buy
402.79%
Upside
Reiterated
Piper remains bullish on Yumanity despite partial clinical hold for YTX-7739Piper remains bullish on Yumanity despite partial clinical hold for YTX-7739
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

YMTX Financial Forecast

YMTX Earnings Forecast
Next quarter’s earnings estimate for YMTX is ― with a range of ― to ―. The previous quarter’s EPS was -$0.31. YMTX beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.49% of the time in the same period. In the last calendar year YMTX has Outperformed its overall industry.
Next quarter’s earnings estimate for YMTX is ― with a range of ― to ―. The previous quarter’s EPS was -$0.31. YMTX beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.49% of the time in the same period. In the last calendar year YMTX has Outperformed its overall industry.
YMTX Sales Forecast
Next quarter’s sales forecast for YMTX is ― with a range of ― to ―. The previous quarter’s sales results were $1.40M. YMTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 42.83% of the time in the same period. In the last calendar year YMTX has Underperformed its overall industry.
Next quarter’s sales forecast for YMTX is ― with a range of ― to ―. The previous quarter’s sales results were $1.40M. YMTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 42.83% of the time in the same period. In the last calendar year YMTX has Underperformed its overall industry.
No data currently available
YMTX Analyst Recommendation Trends
In the current month, YMTX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The YMTX average analyst price target in the past 3 months is ―
In the current month, YMTX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The YMTX average analyst price target in the past 3 months is ―

YMTX Stock Forecast FAQ

What is YMTX’s average 12-month price target, according to analysts?
Currently, no data Available
What is YMTX’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for YMTX, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is YMTX a Buy, Sell or Hold?
      Currently, no data Available
      What is Yumanity Therapeutics’s price target?
      Currently, no data Available
      What do analysts say about Yumanity Therapeutics?
      Not enough analysts have published a price target to provide an average price target.

      What's Included in PREMIUM?
      Make informed decisions based on Top Analysts' activity
      Know what industry insiders are buying
      Get actionable alerts from top Wall Street Analysts
      Find out before anyone else which stock is going to shoot up
      Get powerful stock screeners & detailed portfolio analysis